Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients
Crossref DOI link: https://doi.org/10.1007/s11684-021-0843-8
Published Online: 2021-11-02
Published Print: 2022-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fan, Lei
Wang, Li
Cao, Lei
Zhu, Huayuan
Xu, Wei
Li, Jianyong
Text and Data Mining valid from 2021-11-02
Version of Record valid from 2021-11-02
Article History
Received: 21 July 2020
Accepted: 29 December 2020
First Online: 2 November 2021